Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial

详细信息    查看全文

• 作者：Robert G Fassett (1) (2) (4) (5)
  Helen Healy (1)
  Ritza Driver (2)
  Iain K Robertson (3)
  Dominic P Geraghty (3)
  James E Sharman (4) (5)
  Jeff S Coombes (2) (4)
  
• 刊名：BMC Nephrology
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：9
• 期：1
• 全文大小：570KB
• 参考文献：1. Aakhus S, Dahl K, Wideroe TE: Cardiovascular morbidity and risk factors in renal transplant patients. / Nephrol Dial Transplant 1999,14(3):648鈥?54. CrossRef
  2. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. / Circulation 1999,99(18):2434鈥?439.
  3. Sutherland W, Walker R, Ball M, Stapley S, Robertson M: Oxidation of low density lipoproteins from patients with renal failure or renal transplants. / Transplant Proc 1995, 48:227鈥?36.
  4. Shoskes D, Shahed A, Kim S: Oxidative stress and antioxidant capacity in urine of renal transplant recipients predict early graft function. / Transplant Proc 2001, 33:984. CrossRef
  5. Paragh G, Asztalos L, Seres I: Serum paraoxonase activity changes in uremic and kidnet transplant patients. / Nephron 1999, 83:126鈥?31. CrossRef
  6. Ghanem H, Dorpel M, Weimar W: Increased low density lipoprotein oxidation in stable kidney transplant recipients. / Kidney Int 1996, 49:488鈥?93. CrossRef
  7. Cofan F, Zambon D, Rodriguez C: Oxidation of low-density lipoproteins in renal transplant recipients. / Transplant Proc 1999,31(6):2333鈥?334. CrossRef
  8. Massy ZA, Maziere C, Kamel S, Brazier M, Choukroun G, Tribouilloy C, Slama M, Andrejak M, Maziere JC: Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. / Pediatr Nephrol 2005,20(3):380鈥?82. CrossRef
  9. Fletcher LA, Fassett RG, Richards RS, Coombes JS: Cyclosporine induced oxidative stress and altered antioxidant defences in plasma and erythrocytes. / Redox Report 2005,10(1):2鈥?. CrossRef
  10. Lexis LA, Richards RS, Fassett RG, Coombes JS: Cyclosporine A-induced changes to erythrocyte redox balance is time course-dependent. / Basic Clin Pharmacol Toxicol 2005,97(3):135鈥?40. CrossRef
  11. Lexis LA, Fenning A, Brown L, Fassett RG, Coombes JS: Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-induced vascular dysfunction. / Am J Transplant 2006,6(1):41鈥?9. CrossRef
  12. Rimm E, Stampfer MJ: The role of antioxidants in preventive cardiology. / Curr Opin Cardiol 1997,12(2):188鈥?94. CrossRef
  13. Gey K, Puska P, Jordan P, Moser U: Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. / Am J Clin Nutr 1991,53(1):326S-334S.
  14. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz G, Willett W: Vitamin E consumption and coronary artery disease in men. / N Engl J med 1993,328(20):1450鈥?456. CrossRef
  15. Stampfer MJ, Hennekens C, Manson J, GA C, Rosner B, Willett W: Vitamin E consumption and the risk of coronary heart disease in women. / N Engl J Med 1993,328(20):1444鈥?449. CrossRef
  16. Rimm E, Stampfer MJ, Ascherio A, Giovannucci E, Colditz G, Willett W: Vitamin E consumption and coronary artery disease in men. / N Engl J med 1993,328(20):1450鈥?456. CrossRef
  17. Halliwell B: Oxidative stress, nutrition and health. Experimental strategies for optimisation of nutritional antioxidant intake in humans. / Free Radic Res 1996,25(1):57鈥?4. CrossRef
  18. Levin G, Yeshurun M, Mokady S: In vivo antiperoxidative effect of 9-cis beta-carotene compared with that of the all trans isomer. / Nutr Cancer 1997,27(3):293鈥?97. CrossRef
  19. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial / Lancet 2002,360(9326):23鈥?3.
  20. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. / N Engl J Med 2000,342(3):154鈥?60. CrossRef
  21. Guerin M, Huntley ME, Olaizola M: Haematococcus astaxanthin: applications for human health and nutrition. / Trends Biotechnol 2003,21(5):210鈥?16. CrossRef
  22. Pashkow FJ, Watumull DG, Campbell CL: Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. / Am J Cardiol 2008,101(10A):58D-68D. CrossRef
  23. Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, / et al.: Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. / Mol Cells 2003,16(1):97鈥?05.
  24. Ohgami K, Shiratori K, Kotake S, Nishida T, Mizuki N, Yazawa K, Ohno S: Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. / Invest Ophthalmol Vis Sci 2003,44(6):2694鈥?701. CrossRef
  25. Gross GJ, Lockwood SF: Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). / Life Sci 2004,75(2):215鈥?24. CrossRef
  26. Gross GJ, Hazen SL, Lockwood SF: Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. / Mol Cell Biochem 2006,283(1鈥?):23鈥?0. CrossRef
  27. Iwamoto T, Hosoda K, Hirano R, Kurata H, Matsumoto A, Miki W, Kamiyama M, Itakura H, Yamamoto S, Kondo K: Inhibition of low-density lipoprotein oxidation by astaxanthin. / J Atheroscler Thromb 2000,7(4):216鈥?22.
  28. Mason RP, Walter MF, McNulty HP, Lockwood SF, Byun J, Day CA, Jacob RF: Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. / J Cardiovasc Pharmacol 2006,47(Suppl 1):S7鈥?4. CrossRef
  29. Lauver DA, Driscoll EM, Lucchesi BR: Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. / Pharmacology 2008,82(1):67鈥?3. CrossRef
  30. Kupcinskas L, Lafolie P, Lignell A, Kiudelis G, Jonaitis L, Adamonis K, Andersen LP, Wadstrom T: Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. / Phytomedicine 2008,15(6鈥?):391鈥?99. CrossRef
  31. Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S: Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. / Ophthalmology 2008,115(2):324鈥?33. CrossRef
  32. Comhaire FH, El Garem Y, Mahmoud A, Eertmans F, Schoonjans F: Combined conventional/antioxidant "Astaxanthin" treatment for male infertility: a double blind, randomized trial. / Asian J Androl 2005,7(3):257鈥?62. CrossRef
  33. Bloomer RJ, Fry A, Schilling B, Chiu L, Hori N, Weiss L: Astaxanthin supplementation does not attenuate muscle injury following eccentric exercise in resistance-trained men. / Int J Sport Nutr Exerc Metab 2005,15(4):401鈥?12.
  34. Karppi J, Rissanen TH, Nyyssonen K, Kaikkonen J, Olsson AG, Voutilainen S, Salonen JT: Effects of astaxanthin supplementation on lipid peroxidation. / Int J Vitam Nutr Res 2007,77(1):3鈥?1. CrossRef
  35. Andersen LP, Holck S, Kupcinskas L, Kiudelis G, Jonaitis L, Janciauskas D, Permin H, Wadstrom T: Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin. / FEMS Immunol Med Microbiol 2007,50(2):244鈥?48. CrossRef
  36. Spiller GA, Dewell A: Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. / J Med Food 2003,6(1):51鈥?6. CrossRef
  37. Blackhall ML, Fassett RG, Sharman JE, Geraghty DP, Coombes JS: Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients. / Nephrol Dial Transplant 2005,20(9):1970鈥?975. CrossRef
  38. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ: Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. / J Hypertens 1998,16(12 Pt 2):2079鈥?084. CrossRef
  39. Mori TA, Croft KD, Puddey IB, Beilin LJ: An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. / Anal Biochem 1999,268(1):117鈥?25. CrossRef
  40. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK: Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. / Arterioscler Thromb Vasc Biol 2002,22(5):e10鈥?4. CrossRef
  41. Aeschlimann SE, Mitchell CK, Korcarz CE: Ultrasound brachial artery reactivity testing: technical considerations. / J Am Soc Echocardiogr 2004,17(6):697鈥?99. CrossRef
  42. Dalton BS, Fassett RG, Geraghty DP, De Ryke R, Coombes JS: No relationship between low-density lipoproteins and endothelial function in hemodialysis patients. / Int J Cardiol 2005,99(2):307鈥?14. CrossRef
  43. Mitchell CK, Aeschlimann SE, Korcarz CE: Carotid intima-media thickness testing: technical considerations. / J Am Soc Echocardiogr 2004,17(6):690鈥?92. CrossRef
  44. Chodakauskas TFS: non-invasive measurement of surrogate markers of atherosclerosis: carotid intima thickness (c-IMT). / GE Healthcare 2006.
  45. Stompor T, Krasniak A, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tabor B, Kowalczyk-Michalek ME, Zdzienicka A, Janusz-Grzybowska E: Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. / Nephrol Dial Transplant 2005,20(2):404鈥?12. CrossRef
  46. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. / Transplantation 2005,79(8):914鈥?19. CrossRef
  47. Bahous SA, Stephan A, Blacher J, Safar ME: Aortic stiffness, living donors, and renal transplantation. / Hypertension 2006,47(2):216鈥?21. CrossRef
  48. Hampel DJ, Pratschke J, May G, Reinke P, Schindler R: Living kidney donation: anemia and inflammation in the early postoperative period. / Transplant Proc 2006,38(3):661鈥?63. CrossRef
  49. Mercke Odeberg J, Lignell A, Pettersson A, Hoglund P: Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. / Eur J Pharm Sci 2003,19(4):299鈥?04. CrossRef
  50. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/9/17/prepub
  
• 作者单位：Robert G Fassett (1) (2) (4) (5)
  Helen Healy (1)
  Ritza Driver (2)
  Iain K Robertson (3)
  Dominic P Geraghty (3)
  James E Sharman (4) (5)
  Jeff S Coombes (2) (4)
  
  1. Renal Research, Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland, Australia
  2. Renal Research Tasmania, Launceston General Hospital, Launceston, Tasmania, Australia
  4. School of Human Movement Studies, University of Queensland, St. Lucia, Queensland, Australia
  5. School of Medicine, University of Queensland, St. Lucia, Queensland, Australia
  3. School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia
  

文摘

Background There is evidence that renal transplant recipients have accelerated atherosclerosis manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative stress and inflammation associated with immunosuppressive therapy. The dietary supplement astaxanthin has shown promise as an antioxidant and anti-inflammatory therapeutic agent in cardiovascular disease. The aim of this trial is to investigate the effects of astaxanthin supplementation on arterial stiffness, oxidative stress and inflammation in renal transplant patients. Method and Design This is a randomised, placebo controlled clinical trial. A total of 66 renal transplant recipients will be enrolled and allocated to receive either 12 mg/day of astaxanthin or an identical placebo for one-year. Patients will be stratified into four groups according to the type of immunosuppressant therapy they receive: 1) cyclosporine, 2) sirolimus, 3) tacrolimus or 4) prednisolone+/-azathioprine, mycophenolate mofetil or mycophenolate sodium. Primary outcome measures will be changes in 1) arterial stiffness measured by aortic pulse wave velocity (PWV), 2) oxidative stress assessed by plasma isoprostanes and 3) inflammation by plasma pentraxin 3. Secondary outcomes will include changes in vascular function assessed using the brachial artery reactivity (BAR) technique, carotid artery intimal medial thickness (CIMT), augmentation index (AIx), left ventricular afterload and additional measures of oxidative stress and inflammation. Patients will undergo these measures at baseline, six and 12 months. Discussion The results of this study will help determine the efficacy of astaxanthin on vascular structure, oxidative stress and inflammation in renal transplant patients. This may lead to a larger intervention trial assessing cardiovascular morbidity and mortality. Trial Registration ACTRN12608000159358